Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Registration & accommodation

Registration is closed. The EHA-EBMT 6th European CAR T-cell Meeting provides opportunities for students, trainees, nurses and others to join the meeting for a discounted fee.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

SWG Educational Activities

Social and public EHA-related activitiesX/Twitter accountThe SWG on Infections in Hematology has an account on X (formerly known as Twitter). Our name on X is @EHAInfectionsH1.

Read more

Cookie policy

Introduction
When you visit the EHA website and/or EHA’s resource platform(s) (this includes all websites and pages, with the exemption of www. t2evolve.

Read more

Meeting program

Saturday, November 4*All times are in EET.

Read more